Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Moderna Short Sellers Hit With $4.8 Billion Loss as Stock Soars 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
3 clinical-grade skincare creams you really shouldn’t buy online 
Trump Buys SpaceX Shares After Record IPO 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Yindjibarndi Appeals Fortescue Mining Compensation Ruling 
Nvidia Eyes Perplexity Investment at $30 Billion Valuation 
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
OpenAI Data Center Chief Chris Malone Exits Ahead of Planned 2027 Listing 
Add as a preferred source on Google
SK Biopharmaceuticals has signed a worldwide licensing agreement with Biohaven Bioscience Ireland, securing global rights to the epilepsy drug candidate Opakalim and a portfolio of related Kv7 activator compounds.
The South Korean pharmaceutical company disclosed the agreement in a regulatory filing on Wednesday, marking a significant expansion of its pipeline for neurological treatments. Under the deal, SK Biopharmaceuticals will also gain access to Biohaven Bioscience Ireland's Kv7 discovery platform, which could support the development of additional drug candidates targeting neurological disorders.
The licensing agreement carries a potential total value of $795 million. SK Biopharmaceuticals will make an upfront payment totaling $400 million, including $350 million payable when the transaction closes. A further $50 million payment is scheduled for one year after closing.
In addition to those payments, SK Biopharmaceuticals will pay Biohaven Bioscience Ireland royalties based on net sales of products covered by the agreement. The company did not disclose the royalty rates in its filing.
Opakalim is an epilepsy drug candidate based on Kv7 activation, a mechanism associated with regulating neuronal excitability. By acquiring worldwide rights to Opakalim and other Kv7 activators, SK Biopharmaceuticals is strengthening its focus on epilepsy and central nervous system treatments while adding a broader drug discovery platform to its portfolio.
The transaction also gives SK Biopharmaceuticals control over the future global development and commercialization opportunities associated with the licensed compounds.
SK Biopharmaceuticals has established epilepsy as a key area of its pharmaceutical business, and the Biohaven licensing deal adds another potential treatment to its development pipeline. The inclusion of multiple Kv7 activator compounds and the underlying discovery platform could also provide opportunities beyond Opakalim as the company evaluates additional neurological drug candidates.
If all potential payments under the agreement are reached, the deal could ultimately be worth as much as $795 million, excluding royalties tied to future product sales.
